Search

Researchers at Mount Sinai Hospital in New York City conducted a study comparing the outcomes of two surgical treatments, Holmium laser enucleation of the prostate (HoLEP) and robot-assisted simple prostatectomy (RASP), for medication-refractory benign prostatic hyperplasia (BPH) in patients with prostate volume >= 80 g. The study found that HoLEP and RASP had comparable efficacy in achieving the trifecta outcome of complete urinary continence, Q(max) >15 mL/second, and no postoperative complications at 3 months. HoLEP was preferred for BPH in large prostates due to its shorter hospital stay and catheterization time. Further randomized controlled trials are needed to establish treatment protocols for patients with medication-refractory BPH. [Extracted from the article]

A study conducted at the Northern Ontario School of Medicine compared the use of second-generation MOSES 2.0 technology to MOSES 1.0 technology for holmium laser enucleation of the prostate (HoLEP) in patients with benign prostatic hyperplasia (BPH). The research found that patients who underwent HoLEP with MOSES 2.0 technology had shorter enucleation and hemostasis times, lower laser energy usage, and comparable postoperative outcomes to those who underwent HoLEP with MOSES 1.0 technology. The study concluded that HoLEP with second-generation MOSES 2.0 technology is a safe and effective treatment option for BPH. [Extracted from the article]

A study conducted at the Mayo Clinic in Phoenix, Arizona, examined the impact of a surgical technique called early apical release (EAR) on postoperative stress urinary incontinence (SUI) in patients who underwent Holmium Laser Enucleation of the Prostate (HoLEP) for benign prostatic hyperplasia. The study proposed a novel classification of the external sphincter appearance after HoLEP, graded from 0 (best preserved) to 3 (most degraded). The results showed that lower sphincter grades were associated with improved return of continence after EAR HoLEP. This research provides new insights into the management of SUI in patients undergoing HoLEP. [Extracted from the article]

A new study conducted at the University of Rochester in New York has explored the relationship between HER2 immunohistochemistry (IHC) scores and mRNA levels in estrogen receptor (ER)-positive, HER2-negative breast cancers (BCs). The study found that HER2 mRNA levels correlated better with clinicopathologic features and recurrence risk than HER2 IHC scores. The researchers suggest that HER2 mRNA-detecting methods could potentially serve as a quantitative and reliable method for identifying a biologically meaningful group of HER2-low BCs. Further study is needed to determine whether HER2 mRNA levels could be more reliable than IHC for identifying patients who will benefit from trastuzumab deruxtecan. [Extracted from the article]

A recent study from Duke University in Durham, North Carolina, explores the mechanisms of action in Holmium:yttrium-aluminum-garnet (Ho:YAG) laser lithotripsy (LL), a common treatment for kidney stone disease. The researchers conducted experiments and simulations to understand the physical processes involved in LL. They found that the majority of the laser energy is dissipated as heat in the surrounding fluid and stone surface, with only a small percentage used for photothermal ablation. The study also highlights the importance of shock waves generated by toroidal bubble collapse in kidney stone dusting during LL procedures. [Extracted from the article]

A study conducted by Baylor Scott and White Health in Temple, Texas, examined the predictors of postoperative urinary tract infection (UTI) following holmium laser enucleation of the prostate (HoLEP). The study found that storage urinary symptoms and UTIs are common complications after HoLEP. Factors associated with a higher rate of postoperative UTI at six weeks included high body mass index (BMI), weak grip strength, positive preoperative urine culture, and postoperative urinary incontinence. The study suggests that high BMI, preoperative positive urine culture, higher frailty scale, and postoperative urinary incontinence may be predictors of UTI after HoLEP. [Extracted from the article]

Keywords: Cleveland; State:Ohio; United States; North and Central America; Medical Devices and Surgical Technology; Health and Medicine; Holmium; Holmium Laser; Lanthanoid Series Elements; Medical Devices EN Cleveland State:Ohio United States North and Central America Medical Devices and Surgical Technology Health and Medicine Holmium Holmium Laser Lanthanoid Series Elements Medical Devices 2023 FEB 12 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Investigators discuss new findings in Medical Devices and Surgical Technology. Cleveland, State:Ohio, United States, North and Central America, Medical Devices and Surgical Technology, Health and Medicine, Holmium, Holmium Laser, Lanthanoid Series Elements, Medical Devices. [Extracted from the article]